Skip to main content

Australia to buy extra 20 million doses of Pfizer vaccine

Friday, April 9, 2021 | The Associated Press


In this image made from video, Australian Prime Minister Scott Morrison speaks during a news conference in Canberra, Australia, Thursday, April 8, 2021. Australia on Thursday become the latest country to restrict use of the AstraZeneca vaccine by recommending that it not be given to people under age 50. (SBS via AP)

CANBERRA, Australia (AP) — Australia said Friday that it has finalized a deal to buy an extra 20 million doses of the Pfizer vaccine as it rapidly pivots away from its earlier plan to rely mainly on the AstraZeneca vaccine.

Prime Minister Scott Morrison announced the deal just hours after saying Australia would stop using the AstraZeneca vaccine for people aged under 50.

He said the deal means Australia will get a total of 40 million doses of the Pfizer vaccine by the end of the year, enough to inoculate 20 million people in the nation of 26 million.

Australia's pivot came after the European Medicines Agency said this week it had found a “possible link” between the AstraZeneca vaccine and rare blood clots, though regulators in the United Kingdom and the European Union emphasized that the benefits of receiving the vaccine continue to outweigh the risks for most people.

After the European agency's declaration, Australian drug regulators held a series of urgent meetings Thursday and recommended the Pfizer vaccine become the preferred vaccine for people under 50.

Morrison said there was no prohibition on the AstraZeneca vaccine and the risk of side effects was remote. He said the change was being made out of an abundance of caution.

The pivot represents a significant shift in Australia's overall approach and is likely to delay plans to have everybody inoculated by October.

A major part of Australia’s strategy had been the ability to make its own vaccines at home and not rely on shipments from abroad. It had planned to manufacture some 50 million doses of the AstraZeneca vaccine, enough for 25 million people. Australia had made no plans to make any other vaccines at home.

Even before the change, the government was facing criticism for a rollout program that's lagging behind those in most other developed nations. So far, Australia has administered just over 1 million vaccine doses.

Opposition Leader Anthony Albanese said the rollout was a debacle and Australians needed certainty about when they would be vaccinated.

“This government has failed. This government couldn’t run a choko vine up a back fence,” Albanese told reporters, referring to a plant that produces pear-shaped fruit and grows easily in the Australian climate.

Health Minister Greg Hunt said there would be some adjustments but everybody would be kept safe and would get vaccinated.

Australia has managed to stamp out community spread of the virus, allowing life to continue much as before the pandemic.

AstraZeneca noted Australia’s decision to restrict the vaccine's use was based on it having no community transmission.

“Overall, regulatory agencies have reaffirmed the vaccine offers a high-level of protection against all severities of COVID-19 and that these benefits continue to far outweigh the risks,” the company said in a statement.

Featured Article: Systematic Risk and Investors


7 Precious Metals Stocks That Will Keep Your Portfolio On Trend

The growing acceptance of cryptocurrency is beginning to make mainstream investors rethink their idea of “store of value.” The trendy possibilities of Bitcoin, Ethereum, and any of the dozens of altcoins that exist on the blockchain are trending like the latest fashion.

However, the thing about fashion is that the more things change the more things stay the same. Just like the simple black dress that won’t go out of fashion, the same can be said for precious metals stocks. One way to think about it would be to say that the existence of a growing cryptocurrency market doesn’t change the value of precious metals.

Precious metals have long been known to be a safe-haven asset in times of market volatility and economic crisis. In fact, during the Covid-19 pandemic, gold prices surged about 30% breaking the $2,000 mark for the first time in its history. This was at a time when the prices of many cryptocurrencies were falling.

And precious metals have also been seen as a hedge against inflation, which seems like more of a certainty with the Federal Reserve’s pledge to keep interest rates at historically low rates into 2023.

Whether you’re looking to take your first steps at crafting a precious metals portfolio or if you want to fine-tune the one you have, we believe this special presentation is a good place to start your research. We’ve identified seven precious metals stocks that look to retain their allure in 2021.

View the "7 Precious Metals Stocks That Will Keep Your Portfolio On Trend".


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)2.1$40.02flat3.90%25.82Hold$39.94
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.